A phase 3 trial showed that tarcocimab, a biopolymer with a vascular growth factor antibody, improved vision and anatomical markers in patients with early stage diabetic retinopathy. Medscape Medical News
Tag: Ophthalmology
Children With Sickle Cell Disease at Risk for Vision Loss
Previously thought to be age-dependent, retinopathy affects a full third of children with sickle cell disease, a new study found. Medscape Medical News
FDA Recalls Dozens More Eye Drop Products
More than 2 dozen products could cause eye infections or blindness, after bacterial contamination and unsanitary conditions were found at a manufacturing facility, the agency said. WebMD Health News
Faricimab Efficacy, Safety Hold Up in Real-World Study
A real-world study of faricimab in neovascular age-related macular degeneration showed visual and anatomical improvement in line with phase 3 trials in treatment-naive and previously treated eyes. Medscape Medical News
High-Dose Aflibercept Sustains Outcomes Over 96 Weeks
The recently approved 8-mg dose of aflibercept has shown sustained improvement in vision and anatomical markers out to 96 weeks, according to updated clinical trial results. Medscape Medical News
Eye Specialists Miss Mental Health Issues Linked to AMD
Patients with age-related macular degeneration are known to experience high rates of depression and anxiety, but clinicians often miss the problems, prompting a call for a consensus statement. Medscape Medical News
Implant Shown to Lower Anti-VEGF Burden in DME
The PALADIN study reported the intravitreal fluocinolone acetonide implant reduced the frequency of anti-VEGF injections in patients with diabetic macular edema out to 3 years. Medscape Medical News
Trio Who Invented Eye Test Wins Lasker Prize
‘America’s Nobel’ for medicine recognizes three researchers who developed optical coherence imaging, now widely used in ophthalmology. Medscape Medical News
Glaucoma: A Hidden Threat to Vision Health Rising Swiftly
"Late in the disease, people may notice they’re tripping over the curb, or walking into things they didn’t see. It really is only in very advanced disease that people notice there’s anything wrong." WebMD Health News
Battery Charged by Tears for Smart Contact Lenses
Researchers at Nanyang Technological University in Singapore have developed a tiny, flexible battery that is intended for use in smart contact lenses. The device is as thin as the human cornea and can be charged by a saline solution, which is particularly useful in the eye, as it is full of salty tears. When the […]
Adolescent Eye Health Worse With Vape and Cigarette Use
Using both cigarettes and vapes are apparently much worse for eye health than either product use alone, a new study found. Medscape Medical News
Chatbots as Accurate as Ophthalmologists in Giving Advice
The first study of the quality of ChatGPT answers for topics in eye care has found they’re on par with answers from ophthalmologists, who could not always distinguish human from AI responses. Medscape Medical News
Avoid 2 Eye Drop Products, FDA Advises
The FDA is urging the public to avoid buying or using two different kinds of eye drops because of possible bacterial or fungal contamination. WebMD Health News
Study Questions if Blue Light Blocking Glasses Really Work
Despite claims by their makers, blue light glasses probably don’t reduce eyestrain for people who spend a lot of time looking at computer screens or phones. WebMD Health News
Primary Care Vision Testing Rates in Children Low
Vision testing rates by primary care physicians in children were low and differed by insurance status, an anlysis of pooled data found. MDedge News
Light-Activated Hydrogel Thickens, Reshapes Thinning Cornea
Researchers at the University of Ottawa have developed a light-activated hydrogel treatment for corneal disease. Many of the people who suffer from corneal disease, which can include corneal thinning, are not suitable for a corneal transplant, and obtaining transplants is a challenge for those who are. This technology is intended to assist with thi (Read more...)
Long-Term Outcomes of Pegcetacoplan for GA Show Promise
Results of the 30-month data cut of the 3-year GALE open-label extension trial of pegcetacoplan for geographic atrophy showed that the drug produced clinically meaningful reductions in lesion growth. Medscape Medical News
Complications From Geographic Atrophy Drug Fuel Questions
An extension study found no cases of occlusive retinal vasculitis after 23,000 injections of pegcetacoplan, but a panel received more reports of the complication and dealt with conflicts of interest. Medscape Medical News
Do GLP-1 Agonists Worsen Diabetic Retinopathy?
Patients taking glucagon-like peptide-1 agonists were more likely to progress from nonproliferative diabetic retinopathy to proliferative disease or diabetic macular edema than those who took sodium-glucose cotransporter-2 inhibitors. Medscape Medic…
Biosimilars Comparable to Aflibercept in Macular Disease
Phase 3 registration trials found the comparability of two biosimilars to reference aflibercept in terms of efficacy, safety, pharmacokinetics, and immunogenicity. Medscape Medical News